Matinas biopharma reports third quarter 2021 financial results and operational highlights

– positive efficacy and safety data announced from first two cohorts of patients in ongoing enact study of mat2203 (oral amphotericin b) for treatment of cryptococcal meningitis; dsmb unanimously recommended progression to second half of study –
MTNB Ratings Summary
MTNB Quant Ranking